ARTEMIS: Ravulizumab to Protect Patients With CKD From CSA-AKI and MAKE

Exclusion Criteria

• •Emergency or salvage cardiac surgery is expected at screening or randomization, as assessed by the investigator.
• •Single-vessel CABG without valve surgery is planned.
• •Off-pump surgery is planned (eg, surgery without CPB).
• •Recipient of a solid organ or bone marrow transplantation.
• •Cardiogenic shock, hemodynamic instability, use of intra-aortic balloon pump, extracorporeal membrane oxygenation, or left ventricular assist device within 72 hours of randomization.
• •Active systemic bacterial, viral, or fungal infection within 14 days prior to randomization.
• •History of unexplained, recurrent infection.
• •Any use of KRT or presence of AKI within 30 days of randomization
• •Use of any complement inhibitors, or plasmapheresis or plasma exchange within the year prior to Screening, or planned use during the course of the study.
• •Participant is not willing to be vaccinated against N meningitidis or is unwilling to receive prophylactic treatment with appropriate antibiotics , if needed
• •History of or unresolved N meningitidis infection.